ObjectiveTo understand the latest epidemiological situation of liver cancer worldwide and in China. MethodsThis team organized and briefly interpreted the results of the two reports, the International Agency for Research on Cancer team released the latest global cancer statistics report in its authoritative journal, CA: A Cancer Journal for Clinicians, in April 2024, the research team from the National Center for Chronic and Noncommunicable Disease Control and Prevention at the Chinese Center for Disease Control and Prevention published an article in the Lancet Public Health on the changes in cancer burden in China from 2005 to 2020. The epidemiological trends of liver cancer worldwide and in China from 2018 to 2022, the changes in age-standardized incidencerate by world standard population (ASIRW) and age-standardized mortality rate by world standard population (ASMRW) of liver cancer in countries with different human development index (HDI) and income levels in the world in 2022, the incidence and death of liver cancer in different age groups in the world and China in 2022, and the changes in the disease burden of liver cancer in China from 2005 to 2020 were anlyzed. ResultsIn 2022, there were 865 269 new cases and 757 948 deaths of liver cancer globally, it was the sixth most common malignancy and the third leading cause of cancer-related deaths worldwide. The incidence and mortality of liver cancer worldwide and in China from 2018 to 2022 tended to be stable or declining, which in men were higher than those in women, and which in all population and males in China were higher than those in the world. The ASIRW and ASMRW were the highest in the countries with high HDI and upper-middle income levels. With the increase of age, the ASIRW and ASMRW of liver cancer continued to increase in the world and in China. The average annual percentage changes (AAPCs) in the deaths, ASMRW, year of life loss, and age-standardized year of life loss for all age groups in China from 2005 to 2020 were negative, indicating a downward trend for each of these indicators. The ASMRW of liver cancer increased with the increasing of age in 2020 in China. ConclusionsLiver cancer continues to pose a significant disease burden worldwide and in China. Therefore, implementing primary and secondary prevention strategies for liver cancer in the future is a major measure for its prevention and control. Additionally, continuous efforts are needed to ensure multidisciplinary and standardized management of liver cancer throughout its course.
ObjectiveTo systematically analyze the incidence and mortality of pancreatic cancer globally and in China from 2018–2022 based on GLOBOCAN 2018, 2020, and 2022 editions released by the International Agency for Research on Cancer, and summarize the main influencing factors to provide reference for the formulation of prevention and control strategies and clinical practice of pancreatic cancer in China. MethodsWe collected and organized data on pancreatic cancer incidence cases, mortality cases, crude incidence rate, crude mortality rate, age-standardized incidence rate by world standard population (ASIRW), and age-standardized mortality rate by world standard population (ASMRW) from the GLOBOCAN database. Combined with socioeconomic parameters such as human development index (HDI) and national income levels, we conducted comparative analysis of the distribution characteristics of pancreatic cancer globally and in China across different regions, age groups, and genders. ResultsFrom 2018 to 2022, incidence number of global pancreatic cancer increased from 458 000 cases i to 511 000 cases in 2022, with crude incidence rate rising from 5.4/100 000 to 6.5/100 000. Deaths increased from 432 000 cases to 467 000 cases, with crude mortality rising from 5.7/100 000 to 5.9/100 000, while ASMRW decreased from 4.4/100 000 to 4.3/100 000. In China, incidence number of pancreatic cancer increased from 116 000 cases in 2018 to 119 000 cases in 2022, accounting for 23.3% of global cases, with crude incidence rate maintained at (8–9)/100 000. Deaths decreased from 110 000 cases to 106 000 cases, with crude mortality declining from 7.8/100 000 to 7.5/100 000 and ASMRW decreasing from 4.9/100 000 to 3.9/100 000. In 2022, countries with very high HDI had pancreatic cancer ASIRW of 7.9/100 000 and ASMRW of 6.9/100 000, significantly higher than low HDI countries at 1.4/100 000. Pancreatic cancer incidence showed clear age-related patterns, with the ≥75 age group having 191 157 new cases globally (crude incidence rate of 63.3/100 000) and 37 722 cases in China (crude incidence rate of 51.2/100 000). Both globally and in China, males showed higher incidence rate and mortality than females. ConclusionsPancreatic cancer is becoming an important public health challenge globally and in China, with incidence rate and mortality likely to continue rising in the future. Comprehensive prevention and control measures including tobacco control, obesity management, and diabetes monitoring should be strengthened. Early screening and standardized diagnosis and treatment for high-risk populations are crucial for improving pancreatic cancer survival rates. Improving the national cancer registry system and integrating multidisciplinary collaborative models can lay a solid foundation for precision prevention and treatment of pancreatic cancer.